# Resminostat

Source: https://onco.cc/drugs/resminostat/  
OnCo record `resminostat` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Resminostat is an oral drug of the HDAC inhibitor class, proposed for advanced mycosis fungoides and Sézary syndrome, two cutaneous T-cell lymphomas. Europe's medicines committee said no to it in May 2025, so it is not authorised.

## Summary

Resminostat (Kinselby, applicant 4SC AG, orphan designation) was proposed for the treatment of patients with advanced-stage mycosis fungoides and Sézary syndrome. The CHMP adopted its opinion on 22 May 2025 and the opinion status on the EMA product page is negative, so there is no EU marketing authorisation. The active substance is resminostat mesilate; the EMA lists the therapeutic area as mycosis fungoides. The corpus's approved HDAC inhibitors in cutaneous T-cell lymphoma are romidepsin and vorinostat (target page `hdac`).

## Fields

- Kind: Treatment
- Last checked: 2026-09-22
- Also known as: resminostat; resminostat mesilate; Kinselby; 4SC-201
- Tags: ema-register
- Brand: Kinselby
- Modality: Small-molecule HDAC inhibitor
- Mechanism: Oral histone deacetylase inhibitor proposed for advanced-stage mycosis fungoides and Sézary syndrome; the EMA's committee adopted a negative opinion on the marketing application (EMA product page).

## Sources

- EMA: Kinselby (EPAR): https://www.ema.europa.eu/en/medicines/human/EPAR/kinselby

## Connected records

- drugs: [Romidepsin](https://onco.cc/drugs/romidepsin/)
- cancers: [Cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome)](https://onco.cc/cancers/cutaneous-t-cell-lymphoma/)
- technologies: [Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET)](https://onco.cc/technologies/epigenetic-drugs/)
- targets: [Histone deacetylases (HDAC)](https://onco.cc/targets/hdac/)
- companies: [4SC](https://onco.cc/companies/4sc/)

---
JSON: https://onco.cc/api/v1/entities/resminostat.json